COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

BBV152 vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-07-26)

Evidence profile
2021-07-29

Summary of findings
2021-07-29

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04471519 ; CTRI/2
Bharat Biotech
Ella R, Lancet Infect Dis, 2021

Full text
Commentary
Inactivated virus

BBV152 3mcg + Algel-IMDG

BBV152

BBV152

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India N=375
Low
Details

Full description

NCT04641481
Bharat Biotech
Ella R, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

BBV152

Placebo

RCT
Phase 3
Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India N=25778
Some concerns
Details

Full description

NCT04471519 ; CTRI/2
Bharat Biotech
Ella R, Lancet Infect Dis, 2021

Full text
Commentary
; Commentary
Inactivated virus

BBV152

3mcg BBV152 + Algel-IMDG

RCT
Phase 2
Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India N=380
Some concerns
Details

Full description